Research and Markets: Partnering Agreements With Alcon 2010 - An In-Depth Insight Into One of the World's Leading Biopharma Companies
Business Wire, 04.02.2010

Research and Markets (http://www.researchandmarkets.com/research/8ef3e4/partnering_agreeme) has announced the addition of the "Partnering Agreements with Alcon 2010" company profile to their offering.

The Partnering Agreements with Alcon 2010 provides an in-depth insight into the partnering interests and activities of one of the world's leading biopharma companies.

This report provides all the information you require to better understand Alcon and its partnering interests and activities over the past five years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently determine the suitability of Alcon as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners.

The report provides a firm basis for initial due diligence into Alcon as a prospective partner company.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers between 2005 and 2009 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005 to 2009 according to reported deal size.

Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

Chapter 7 provides a series of matrices that summarize the company's activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area.

The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company's marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In summary, the report provides the user with the tools to make successful contact with the right bigpharma partners effectively and efficiently.

Partnering Agreements with Alcon 2010 report provides the user with the following key benefits:

• Detailed company profile of the company
• In-depth marketed and pipeline product activity for the company
• Partnering interests and therapy focus revealed
• Partnering activity since 2000 number of deals per year
• Partnering activity for 2005-2009
• - Activity by deal type
• - Activity by phase of development
• - Activity by therapeutic area
• - List of recent partner companies
• Comprehensive access to actual contracts entered into by the company and its partners*
• Insight into the terms included in a partnering agreement
• Understand the key deal terms the company has agreed in previous deals

Partnering Agreements with Alcon 2010 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's approach to partnering.

Partnering Agreements with Alcon 2010 includes:

• Detailed company profile including:
• - Full contact details
• - Business developer contact details including name, title, email and telephone (where available)
• - Marketed indications
• - Pipeline indications
• - Partnering interests and indications
• - Partnering activity since 2000
• - Current partner companies since 2005
• - Partnering activity since 2005 by:
• -- Deal type
• -- Stage of development
• -- Therapy area
• Numerous charts showing the dealmaking activity of the company since 2005
• The tools to enable effective and efficient preparation for partnering negotiation with the company
• Listing of contract documents between the company and its partners
• The leading M&A and partnering deals by value 2005-2009
• Most active M&A and partnering dealmakers 2005-2009

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Bigpharma The Top 50

Chapter 3 Most active bigpharma dealmakers

Chapter 4 Top bigpharma deals by value

Chapter 5 Submitting Opportunities to Bigpharma such as Alcon

Chapter 6 Forthcoming bigpharma partnering events

Chapter 7 Alcon therapy locator

Chapter 8 Bigpharma Company Profiles Alcon

For more information visit http://www.researchandmarkets.com/research/8ef3e4/partnering_agreeme.

<- Back